ClinicalTrials.gg
TerminatedNCT03602261Updated Apr 3, 2026Results posted

Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI

A Phase 2 interventional study of Calcifediol Oral Capsule and Placebo oral capsule in Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases and Vitamin D Deficiency, sponsored by OPKO Health, Inc.. Terminated at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by OPKO Health, Inc. · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Cohort 1 completed and cohort 2 terminated prior to initiation per company decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 168 open to participants now, 215 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Enrollment
503rd of 819
44 · median 72
Started
2018
with 45 others
Phase 2
156 of 988
21 open now
Registered
551st of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 503rd largest by enrollment of the 819 interventional ones that give a count, is one of 46 that started in 2018, is one of 156 in phase 2, and was the 551st registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

168 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI

Read the detailed description

A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of CTAP101 (calcifediol) Extended-Release Capsules to Treat Secondary Hyperparathyroidism (SHPT) in Subjects with Vitamin D Insufficiency (VDI) and Chronic Kidney Disease Requiring Regular Hemodialysis.

03

Conditions studied

  • Secondary Hyperparathyroidism Due to Renal Causes
  • Chronic Kidney Diseases
  • Vitamin D Deficiency
  • Stage 5 Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Each subject must meet the following criteria to be enrolled in this study:

  1. Be at least 18 years of age.
  2. Be diagnosed with CKD requiring in-center HD tiw for the preceding 6 months, as confirmed by medical history.
  3. Be without any disease state or physical condition that might impair evaluation of safety or which, in the investigator's opinion, would interfere with study participation, including:

    1. Serum albumin ≤ 3.0 g/dL; and,
    2. Serum transaminase ( [ALT], glutamic pyruvic transaminase [SGPT], aspartate aminotransferase [AST] or glutamic oxaloacetic transaminase [SGOT]) > 2.5 times the at screening.
  4. Be receiving calcimimetic therapy (either etelcalcetide or cinacalcet) and/or calcitriol or other 1α-hydroxylated vitamin D analog (paricalcitol or doxercalciferol) for at least 1 month at the time of screening for enrollment. Approximately 50% of enrolled subjects will have been receiving calcimimetic therapy.
  5. Exhibit during the initial screening visit:

    1. Plasma iPTH ≥150 pg/mL and \<600 pg/mL if receiving etelcalcetide, cinacalcet, calcitriol or other 1α-hydroxylated vitamin D analog (paricalcitol or doxercalciferol); or
    2. Plasma iPTH ≥300 pg/mL and \<900 pg/mL if not receiving etelcalcetide, cinacalcet, calcitriol or other 1α- hydroxylated vitamin D analog; and,
    3. Serum total 25-hydroxyvitamin D \<30 ng/mL if not receiving vitamin D supplementation.
  6. When otherwise confirmed eligible at Visit 1, must forgo any further treatment with etelcalcetide and cinacalcet for the duration of the study and undergo an 8-week .
  7. When otherwise confirmed eligible at Visit 1, must forgo any further treatment with calcitriol or other 1α-hydroxylated vitamin D analogs or vitamin D supplements for the duration of the study and undergo an 8-week washout period.
  8. Exhibit after the 8-week washout period (if required due to prior use of etelcalcetide, cinacalcet, calcitriol or other 1α- hydroxylated vitamin D analogs, or vitamin D supplementation):

    1. Plasma iPTH increased by at least 50%;
    2. Plasma iPTH ≥300 pg/mL and \<1,200 pg/mL;
    3. Corrected serum calcium \<9.8 mg/dL;
    4. Serum total 25-hydroxyvitamin D \<50 ng/mL; and,
    5. Serum phosphorus \<6.5 mg/dL.
  9. When otherwise confirmed eligible at Visit 1, if taking more than 1,000 mg per day of elemental calcium, reduce calcium use (to ≤1,000 mg per day) and/or use non-calcium based phosphate binder therapies (as needed) for the duration of the study.
  10. When otherwise confirmed eligible at Visit 1, if taking bone metabolism therapies that may interfere with study endpoints, must discontinue use of these agents for the duration of the study.
  11. Willing and able to comply with study instructions and commit to all clinic visits for the duration of the study.
  12. Female subjects of must be neither pregnant nor lactating and must have a negative serum betahuman chorionic gonadotropin (b-hCG) pregnancy test at the first screening visit and at other scheduled times.
  13. All female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use effective (eg, implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence, vasectomy or vasectomized partner) for the duration of the study.
  14. Be able to read, understand and sign the subject Form (ICF) or have a legal representative sign the ICF.

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from the study:

  1. Scheduled kidney transplant or parathyroidectomy.
  2. History (prior 2 months) of corrected serum calcium ≥9.8 mg/dL or serum phosphorus

    ≥6.5 mg/dL if not receiving calcitriol or other 1α-hydroxylated vitamin D analog.

  3. Receipt of bisphosphonate therapy or other bone modifying treatment (eg, denosumab) within 6 months prior to enrollment.
  4. Known previous or concomitant serious illness or medical condition, such as , , significant gastrointestinal or hepatic disease, intestinal malabsorption disorder, hepatitis or cardiovascular event that in the opinion of the investigator may worsen or reduce , and/or interfere with participation in the study.
  5. History of neurological/psychiatric disorder, including psychotic disorder or dementia, or any reason which, in the opinion of the investigator makes adherence to a treatment or follow-up schedule unlikely.
  6. Known or suspected to any of the constituents of the study drugs.
  7. Currently participating in, or has participated in, an interventional/ study within 30 days prior to study screening.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
44 participants (actual)

Study arms

  • Active comparator
    CTAP101 Capsules 900mcg/weekly

    CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 900mcg/weekly for 26 weeks

    Drug: Calcifediol Oral Capsule

  • Placebo comparator
    Placebo Capsules weekly

    Placebo Oral Capsules/weekly for 26 weeks

    Drug: Placebo oral capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Response During Efficacy Assessment Period

    To evaluate the efficacy of repeated dosing with 900 mcg per week of CTAP101 extended release (ER) Capsules versus placebo in raising mean serum total 25-hydroxyvitamin D (25D) to ≥50 ng/mL and in reducing mean plasma intact parathyroid hormone (iPTH) by at least 30% from pre-treatment baseline.

    Time frame: 26 weeks

  2. Total 25-hydroxyvitamin D Response Analysis During Efficacy Period

    Summary of participants with mean serum total 25-hydroxyvitamin D ≥50 ng/mL at the end of treatment

    Time frame: 26 weeks

  3. Number of Participants With Intact Parathyroid Hormone (iPTH) Response During Efficacy Assessment Period

    Summary of participants who experienced a reduction in mean plasma iPTH by greater than 30% from the pre-treatment baseline

    Time frame: 26 weeks

  4. Pharmacokinetic (PK) Profile (Cmax) of Serum Calcifediol

    To assess Cmax of serum calcifediol after a single dose of 900 mcg at the start of the study (Single Dose PK Period), and a repeat dose of 300 mcg at the end of the study (Repeat Dose PK Period)

    Time frame: 0, 4, 8, 12, 16, 20, 24, 30, 36, 42 and 48 hours post-dose (single and repeat dose)

  5. Pharmacokinetic (PK) Profile (Tmax) of Serum Calcifediol

    To assess Tmax of serum calcifediol after a single dose of 900 mcg at the start of the study (Single Dose PK Period), and a repeat dose of 300 mcg at the end of the study (Repeat Dose PK Period)

    Time frame: 0, 4, 8, 12, 16, 20, 24, 30, 36, 42 and 48 hours post-dose (single and repeat dose)

  6. Pharmacokinetic (PK) Profile (AUC0-t) of Serum Calcifediol

    To assess AUC0-t of serum calcifediol after a single dose of 900 mcg at the start of the study (Single Dose PK Period), and a repeat dose of 300 mcg at the end of the study (Repeat Dose PK Period)

    Time frame: 0, 4, 8, 12, 16, 20, 24, 30, 36, 42 and 48 hours post-dose (single and repeat dose)

Secondary outcomes

  1. Pharmacodynamic Analysis of 1,25-dihydroxyvitamin D

    Effect of CTAP101 on 1,25-dihydroxyvitamin D

    Time frame: 26 weeks

07

Results

Posted Mar 30, 2025

Participant flow

Participant flow — Overall Study
MilestoneCTAP101 Capsules 900mcg/WeeklyPlacebo Capsules Weekly
Started3311
Completed258
Not completed83
Withdrew: Adverse event51
Withdrew: Physician decision10
Withdrew: Withdrawal by subject11
Withdrew: Lack of efficacy01
Withdrew: Subject moving out of state10

Outcome measures

PrimaryNumber of Participants With Response During Efficacy Assessment Period

To evaluate the efficacy of repeated dosing with 900 mcg per week of CTAP101 extended release (ER) Capsules versus placebo in raising mean serum total 25-hydroxyvitamin D (25D) to ≥50 ng/mL and in reducing mean plasma intact parathyroid hormone (iPTH) by at least 30% from pre-treatment baseline.

Time frame:
26 weeks
Reported as:
Count of participants · Participants
Number of Participants With Response During Efficacy Assessment Period
ParticipantsCTAP101 Capsules 900mcg/WeeklyPlacebo Capsules Weekly
Number of Participants With Response During Efficacy Assessment Period40
Statistical analysis
  • CTAP101 Capsules 900mcg/Weekly vs Placebo Capsules Weekly · Fisher Exact · p = 0.5536
PrimaryTotal 25-hydroxyvitamin D Response Analysis During Efficacy Period

Summary of participants with mean serum total 25-hydroxyvitamin D ≥50 ng/mL at the end of treatment

Time frame:
26 weeks
Reported as:
Count of participants · Participants
Total 25-hydroxyvitamin D Response Analysis During Efficacy Period
ParticipantsCTAP101 Capsules 900mcg/WeeklyPlacebo Capsules Weekly
Total 25-hydroxyvitamin D Response Analysis During Efficacy Period281
PrimaryNumber of Participants With Intact Parathyroid Hormone (iPTH) Response During Efficacy Assessment Period

Summary of participants who experienced a reduction in mean plasma iPTH by greater than 30% from the pre-treatment baseline

Time frame:
26 weeks
Reported as:
Count of participants · Participants
Number of Participants With Intact Parathyroid Hormone (iPTH) Response During Efficacy Assessment Period
ParticipantsCTAP101 Capsules 900mcg/WeeklyPlacebo Capsules Weekly
Number of Participants With Intact Parathyroid Hormone (iPTH) Response During Efficacy Assessment Period40
PrimaryPharmacokinetic (PK) Profile (Cmax) of Serum Calcifediol

To assess Cmax of serum calcifediol after a single dose of 900 mcg at the start of the study (Single Dose PK Period), and a repeat dose of 300 mcg at the end of the study (Repeat Dose PK Period)

Time frame:
0, 4, 8, 12, 16, 20, 24, 30, 36, 42 and 48 hours post-dose (single and repeat dose)
Reported as:
Mean · ng/mL
Pharmacokinetic (PK) Profile (Cmax) of Serum Calcifediol
ng/mLCTAP101 Capsules 900mcg
Cmax (single PK)45.5 ± 20.17
Cmax (repeat PK)181.0 ± 171.92
PrimaryPharmacokinetic (PK) Profile (Tmax) of Serum Calcifediol

To assess Tmax of serum calcifediol after a single dose of 900 mcg at the start of the study (Single Dose PK Period), and a repeat dose of 300 mcg at the end of the study (Repeat Dose PK Period)

Time frame:
0, 4, 8, 12, 16, 20, 24, 30, 36, 42 and 48 hours post-dose (single and repeat dose)
Reported as:
Mean · hours
Pharmacokinetic (PK) Profile (Tmax) of Serum Calcifediol
hoursCTAP101 Capsules 900mcg
Tmax (single PK)0.6 ± 0.41
Tmax (repeat PK)2.5 ± 2.72
PrimaryPharmacokinetic (PK) Profile (AUC0-t) of Serum Calcifediol

To assess AUC0-t of serum calcifediol after a single dose of 900 mcg at the start of the study (Single Dose PK Period), and a repeat dose of 300 mcg at the end of the study (Repeat Dose PK Period)

Time frame:
0, 4, 8, 12, 16, 20, 24, 30, 36, 42 and 48 hours post-dose (single and repeat dose)
Reported as:
Mean · hour x ng/mL
Pharmacokinetic (PK) Profile (AUC0-t) of Serum Calcifediol
hour x ng/mLCTAP101 Capsules 900mcg
AUC0-t (single PK)9118.4 ± 3557.65
AUC0-t (repeat PK)95820.7 ± 44858.77
SecondaryPharmacodynamic Analysis of 1,25-dihydroxyvitamin D

Effect of CTAP101 on 1,25-dihydroxyvitamin D

Time frame:
26 weeks
Reported as:
Mean · pg/mL
Pharmacodynamic Analysis of 1,25-dihydroxyvitamin D
pg/mLCTAP101 Capsules 900mcg/WeeklyPlacebo Capsules Weekly
Baseline9.4 ± 1.212.6 ± 2.7
Visit 2450.7 ± 7.813.4 ± 4.1

Adverse events

Collected over 26 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CTAP101 Capsules 900mcg/Weekly0/32 (0%)15/32 (46.9%)29/32 (90.6%)
Placebo Capsules Weekly0/11 (0%)4/11 (36.4%)9/11 (81.8%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventCTAP101 Capsules 900mcg/WeeklyPlacebo Capsules Weekly
Corona virus infectionInfections and infestations3/321/11
OsteomyelitisInfections and infestations3/321/11
PneumoniaInfections and infestations0/321/11
Urinary tract infection staphylococcalInfections and infestations0/321/11
Demyelinating polyneuropathyNervous system disorders0/321/11
Atrial fibrillationCardiac disorders0/321/11
BradycardiaCardiac disorders0/321/11
Cardiac arrestCardiac disorders0/321/11
Incision site complicationInjury, poisoning and procedural complications0/321/11
Gastrointestinal haemorrhageGastrointestinal disorders1/321/11
Most frequent other events
Showing 10 of 93
Most frequent other events
EventCTAP101 Capsules 900mcg/WeeklyPlacebo Capsules Weekly
HypotensionVascular disorders5/323/11
DiarrhoeaGastrointestinal disorders5/321/11
ConstipationGastrointestinal disorders4/320/11
NauseaGastrointestinal disorders4/320/11
TachycardiaCardiac disorders3/320/11
VomitingGastrointestinal disorders3/320/11
MalaiseGeneral disorders3/320/11
Urinary tract infectionInfections and infestations3/321/11
Accidental overdoseInjury, poisoning and procedural complications3/320/11
Vascular access malfunctionInjury, poisoning and procedural complications3/320/11

Baseline characteristics

Modified intention-to-treat (mITT) population.

Age, Customized
Age, Customized(Participants)CTAP101 Capsules 900mcg/WeeklyPlacebo Capsules WeeklyTotal
< 65 years old21728
>= 65 years old729
Sex: Female, Male
Sex: Female, Male(Participants)CTAP101 Capsules 900mcg/WeeklyPlacebo Capsules WeeklyTotal
Female12517
Male16420
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CTAP101 Capsules 900mcg/WeeklyPlacebo Capsules WeeklyTotal
Hispanic or Latino549
Not Hispanic or Latino23528
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CTAP101 Capsules 900mcg/WeeklyPlacebo Capsules WeeklyTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American20525
White7411
More than one race000
Unknown or Not Reported000
08

Study locations

18 sites
  • AKDHC Medical Research Services
    Peoria, Arizona 85381, United States
  • AKDHC Medical Research Services
    Phoenix, Arizona 85027, United States
  • AKDHC Medical Research Services
    Phoenix, Arizona 85035, United States
  • AKDHC Medical Research Services
    Phoenix, Arizona 85258, United States
  • WCCT Global, Inc.
    Cypress, California 90630, United States
  • Hacienda Dialysis Center
    Hacienda Heights, California 91745, United States
  • California Institute of Renal Research CKD/Dialysis & Transplant Division
    La Mesa, California 91942, United States
  • Long Beach Quest Dialysis Center
    Long Beach, California 90807, United States
  • Ontario Dialysis Center
    Ontario, California 91762, United States
  • North America Research Institute, Inc.
    San Dimas, California 91773, United States
  • Laurel Canyon Dialysis, LLC
    Sun Valley, California 91352, United States
  • University of Colorado Denver Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • Research by Design, LLC
    Chicago, Illinois 60643, United States
  • Northshore University Health
    Evanston, Illinois 60201, United States
  • Renal and Transplant Associates of New England
    Springfield, Massachusetts 01107, United States
  • Southwest MS Nephrology
    McComb, Mississippi 39601, United States
  • Southwest Houston Research LTD
    Houston, Texas 77099, United States
  • Kidney & Hypertension Specialists
    San Antonio, Texas 78207, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Feb 2021, 31 months.

Results were first posted in Mar 2025, 4 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2018
First posted
Jul 26, 2018
StartActual
Jul 9, 2018
Primary completionActual
Feb 24, 2021
CompletionActual
Feb 24, 2021
Results first posted
Mar 30, 2025
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03602261
Lead sponsor
OPKO Health, Inc.
Responsible party
Sponsor
First posted
Jul 26, 2018
Start date
Jul 9, 2018
Primary completion
Feb 24, 2021
Completion
Feb 24, 2021
Results posted
Mar 30, 2025
Last update
Apr 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Calcifediol

Start the discussion